Comprehensive safety analysis across over 11,000 participants established that semaglutide has an overall favorable risk/benefit profile with no unexpected safety signals and low rates of serious adverse events
Microdosing may be considered for patients with coexisting conditions such as autoimmune disease, chronic pain, or other factors that warrant a gentler approach
Perch tirzepatide riduce lINR
How is a root-cause approach to weight loss different from Ozempic alone
Key monitoring parameters should include frequency and severity of binge episodes (using standardized measures such as the Binge Eating Scale or Eating Disorder Examination-Questionnaire), weight and metabolic parameters, gastrointestinal side effects, mood and anxiety symptoms, and importantly, any emergence of new disordered eating patterns such as restrictive eating or compensatory behaviors
Which GLP-1 has fewer side effects